ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Sildenafil: Pediatric drug information

Sildenafil: Pediatric drug information
(For additional information see "Sildenafil: Drug information" and see "Sildenafil: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Liqrev;
  • Revatio;
  • Viagra
Brand Names: Canada
  • ACCEL-Sildenafil;
  • AG-Sildenafil;
  • APO-Sildenafil;
  • APO-Sildenafil R [DSC];
  • AURO-Sildenafil;
  • BIO-Sildenafil;
  • JAMP-Sildenafil;
  • JAMP-Sildenafil R;
  • M-Sildenafil;
  • Mar-Sildenafil;
  • MINT-Sildenafil;
  • NRA-Sildenafil;
  • PMS-Sildenafil R;
  • Priva-Sildenafil [DSC];
  • PRZ-Sildenafil;
  • Revatio;
  • RIVA-Sildenafil;
  • TEVA-Sildenafil;
  • TEVA-Sildenafil R;
  • Viagra
Therapeutic Category
  • Phosphodiesterase Type-5 (PDE5) Inhibitor
Dosing: Neonatal

Dosage guidance:

Dosage form information: Oral suspensions may be available in multiple concentrations (commercially available: 10 mg/mL; extemporaneous preparation: 2.5 mg/mL); dosing should be presented in mg of sildenafil; use extra precaution when verifying product formulation and calculation of dose volumes. The 2 mL oral syringe included with the 10 mg/mL oral suspension only provides measurements for fixed doses of 5 mg and 20 mg; for patients not receiving either of these fixed doses, an appropriate-size calibrated oral syringe should be dispensed.

Pulmonary hypertension

Pulmonary hypertension: Limited data available:

Persistent pulmonary hypertension in the neonate (PPHN): Note: Optimal dose and duration of therapy not established; interpatient variability has been reported.

GA >34 weeks:

Oral: Note: Guidelines suggest sildenafil may be used as adjunctive therapy in PPHN refractory to inhaled nitric oxide especially when oxygenation index (OI) >25 (Ref).

Initial: Oral: 0.5 to 1 mg/kg/dose every 6 to 8 hours; titrate as needed; usual reported range: 0.5 to 2 mg/kg/dose every 6 to 8 hours (Ref); doses as high as 3 mg/kg/dose every 6 hours have been reported for short-term treatment; however, chronic treatment with doses >2 mg/kg/dose are not recommended in children and adolescents due to a dose-dependent increased mortality risk observed in trials (Ref).

IV:

Continuous IV infusion: Loading dose: IV: 0.4 mg/kg loading dose administered over 3 hours followed by continuous IV infusion of 1.6 mg/kg/day (~0.07 mg/kg/hour) (Ref). Note: This regimen is recommended in neonates with congenital diaphragmatic hernia (CDH) (Ref).

Intermittent IV infusion: IV: Initial dose: 0.125 to 0.5 mg/kg/dose every 6 to 8 hours; titrate doses as necessary; doses have been increased in increments of 0.125 to 0.5 mg/kg/dose; usual maximum dose: 1 mg/kg/dose up to 10 mg/dose; maximum reported dose: 2 mg/kg/dose (Ref).

Bronchopulmonary dysplasia (BPD) associated pulmonary hypertension:

PMA ≥36 weeks:

Oral: 0.25 to 0.5 mg/kg/dose every 6 to 8 hours; titrate gradually as tolerated up to 1 mg/kg/dose; maximum reported dose: 8 mg/kg/day (Ref).

IV: Initial: 0.25 to 0.5 mg/kg/dose every 6 to 8 hours (Ref).

Pulmonary hypertension, facilitation of inhaled nitric oxide wean

Pulmonary hypertension, facilitation of inhaled nitric oxide (iNO) wean (in patients who previously failed iNO wean): Note: Limited information exists; a wide range of doses and interpatient variability has been reported; careful dose titration is necessary; most literature consists of case reports or small studies.

Full-term neonates:

One-time dose:

Oral: 0.25 to 0.3 mg/kg/dose administered 60 to 70 minutes prior to iNO discontinuation; if initial sildenafil dose does not result in successful iNO weaning, sildenafil may be repeated in 12 hours at a dose of 0.4 mg/kg/dose administered 60 minutes prior to iNO discontinuation (Ref).

IV: 0.125 mg/kg/dose administered 60 minutes prior to iNO discontinuation; if initial sildenafil dose does not result in successful iNO weaning, sildenafil may be repeated in 12 hours at a dose of 0.2 mg/kg/dose administered 60 minutes prior to iNO discontinuation (Ref).

Multiple dose: Oral: Initial: 0.3 mg/kg/dose (range: 0.22 to 0.47 mg/kg/dose) every 6 hours (average duration: 28 days) was used in seven patients (median age: 12 months; range: 3 days to 21 months); optimal duration of treatment not established (Ref).

Dosing: Pediatric

Dosage guidance:

Dosage form information: Oral suspensions may be available in multiple concentrations (commercially available: 10 mg/mL; extemporaneous preparation: 2.5 mg/mL); dosing should be presented in mg of sildenafil; use extra precaution when verifying product formulation and calculation of dose volumes. The 2 mL oral syringe included with the 10 mg/mL oral suspension only provides measurements for fixed doses of 5 mg and 20 mg; for patients not receiving either of these fixed doses, an appropriate-size calibrated oral syringe should be dispensed.

Pulmonary arterial hypertension

Pulmonary arterial hypertension:

Infants: Limited data available; duration of therapy not established; interpatient variability has been reported: Oral: Initial: 0.25 mg/kg/dose every 6 hours or 0.5 mg/kg/dose every 8 hours; titrate as needed; maximum reported dose range: 1 to 2 mg/kg/dose every 6 to 8 hours (Ref). Note: May consider lower initial doses (eg, 0.25 mg/kg/dose every 8 hours) in critically ill patients receiving concomitant vasoactive agents, especially infants <4 months of age (Ref).

Children and Adolescents <18 years:

≤20 kg: Oral: 10 mg three times daily.

>20 to 45 kg: Oral: 20 mg three times daily.

>45 kg: Oral: 20 mg three times daily; titrate as needed; maximum dose: 40 mg/dose.

Pulmonary hypertension, congenital heart disease

Pulmonary hypertension, congenital heart disease (postoperative): Limited data available:

Oral (or nasogastric tube): Dosing regimens variable (Ref):

Infants, Children, and Adolescents: Oral (or nasogastric tube): Initial: 0.5 mg/kg/dose increase in 0.5 mg/kg/dose increments every 4 to 6 hours up to a maximum dose of 2 mg/kg/dose as tolerated; upon discontinuation of mechanical ventilation, sildenafil therapy can be tapered over 5 to 7 days (Ref). Note: Use of preoperative sildenafil therapy for the prevention of pulmonary hypertension following congenital heart surgery has been reported and has produced variable efficacy results (Ref).

IV: Dosing regimens variable (Ref):

Infants >60 days and Children: IV: Loading dose: Range: 0.04 to 0.35 mg/kg administered over 5 minutes, followed by a maintenance infusion: Reported range: 0.015 to 0.4 mg/kg/hour continued for 24 to 72 hours (Ref).

Pulmonary hypertension, facilitation of inhaled nitric oxide wean

Pulmonary hypertension, facilitation of inhaled nitric oxide (iNO) wean (in patients who have not previously failed iNO wean): Limited data available:

Infants and Children ≤15 months: Oral (nasogastric): Single dose: 0.4 mg/kg/dose (range: 0.3 to 0.5 mg/kg/dose) given once 60 minutes prior to iNO discontinuation (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Revatio: Children and Adolescents: Oral, IV: Mild, moderate, and severe impairment: No dosage adjustment necessary.

Dosing: Hepatic Impairment: Pediatric

Revatio: Children and Adolescents: Oral, IV:

Mild to moderate impairment: No dosage adjustment necessary.

Severe impairment: There are no dosage recommendations in the manufacturer's labeling (has not been studied).

Dosing: Adult

(For additional information see "Sildenafil: Drug information")

Dosage guidance:

Safety: Do not administer in patients taking nitrates (regularly or intermittently) due to risk for severe hypotension. If a patient taking sildenafil develops chest pain, delay therapy with a nitrate for 24 hours. For patients taking an alpha-blocking antihypertensive agent, use sildenafil with caution and consider a lower starting dose, as sildenafil can potentiate hypotensive effects (Ref). Some experts recommend against routinely using these drugs together, particularly in patients with cardiovascular disease (Ref).

Erectile dysfunction

Erectile dysfunction:

Oral: 50 mg once daily as needed 1 hour before sexual activity; may be taken up to 4 hours before sexual activity. Reduce to 25 mg once daily if side effects occur. May increase to a maximum dose of 100 mg once daily if there is incomplete response.

High-altitude pulmonary edema

High-altitude pulmonary edema (adjunctive therapy) (alternative agent) (off-label use):

Prevention: Note: May use as an adjunct to gradual ascent in high-risk individuals (eg, history of high-altitude pulmonary edema) who cannot take nifedipine (Ref).

Oral: 50 mg every 8 hours starting the day of ascent; continue for 3 to 5 days after reaching maximal altitude (Ref); can extend for up to 7 days in individuals who ascend faster than recommended (Ref).

Treatment: Note: Alternative agent when nifedipine is not available. Adjunctive to nonpharmacologic measures (eg, oxygen supplementation, portable hyperbaric chamber, gradual descent) or as monotherapy if nonpharmacologic measures are not possible (Ref).

Oral: 50 mg every 8 hours; continue until descent is complete, symptoms resolve, and oxygenation is normal for the altitude (Ref).

Pulmonary arterial hypertension

Pulmonary arterial hypertension: Note: Consult a pulmonary arterial hypertension specialist for all management decisions; choice of therapy is dependent on etiology, risk stratification, and cardiopulmonary comorbidities. Sildenafil is contraindicated in patients taking riociguat due to potentially severe hypotension (Ref).

Oral: 20 mg 3 times daily; some do not recommend titration to higher doses (Ref). However, in patients who fail to demonstrate or maintain an adequate clinical response, others consider slowly increasing the dose in 20 mg increments to a maximum dose of 80 mg 3 times daily (Ref).

IV: 10 mg 3 times daily.

Raynaud phenomenon

Raynaud phenomenon (alternative agent) (off-label use):

Oral: Initial: 20 mg once or twice daily; based on response and tolerability, may increase to 20 mg 3 times daily as needed; if lower doses are ineffective, may increase further to 40 mg 3 times daily if tolerated (Ref); others have reported using 50 mg 2 to 3 times daily as tolerated (Ref).

Conversion between oral sildenafil and IV sildenafil: A 10 mg IV sildenafil dose is expected to provide similar effects as a 20 mg oral dose (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Note: Although only 13% of sildenafil is excreted in the urine, the AUC is approximately doubled in patients with CrCl <30 mL/minute, most likely due to a decrease in hepatic function associated with uremia (Ref); use with caution when initiating therapy or with any increase in dose in these patients, including patients on renal replacement therapies. Additionally, although there are no specific dosage adjustments recommended for off-label indications (has not been studied), the same general dosing principles may apply for these indications in patients with altered kidney function or on renal replacement therapies (Ref).

Altered kidney function: Oral, IV:

CrCl ≥30 mL/minute: No dosage adjustment necessary.

CrCl <30 mL/minute:

Pulmonary arterial hypertension: No dosage adjustment necessary; use with caution (Ref).

Erectile dysfunction: Initial: 25 mg once daily as needed 1 hour before sexual activity; may be taken up to 4 hours before sexual activity (Ref). May cautiously increase dose based on tolerability and response. Maximum dose: 100 mg once daily.

Hemodialysis, intermittent (thrice weekly): Oral, IV: Not dialyzable (Ref):

Pulmonary arterial hypertension: No dosage adjustment necessary; use with caution (Ref).

Erectile dysfunction: Initial: 25 mg once daily as needed 1 hour before sexual activity; may be taken up to 4 hours before sexual activity (Ref). May cautiously increase dose based on tolerability and response. Maximum dose: 100 mg once daily (Ref).

Peritoneal dialysis: Oral, IV: Unlikely to be significantly dialyzable (highly protein bound) (Ref):

Pulmonary arterial hypertension: No dosage adjustment necessary; use with caution (Ref).

Erectile dysfunction: Initial: 25 mg once daily as needed 1 hour before sexual activity; may be taken up to 4 hours before sexual activity (Ref). May cautiously increase dose based on tolerability and response. Maximum dose: 100 mg once daily (Ref).

CRRT: Oral, IV:

Pulmonary arterial hypertension: There are no specific dosage adjustments recommended (has not been studied); however, dosage adjustment is likely unnecessary; use with caution (Ref).

PIRRT (eg, sustained, low-efficiency diafiltration): Oral, IV:

Pulmonary arterial hypertension: There are no specific dosage adjustments recommended (has not been studied); however, dosage adjustment is likely unnecessary; use with caution (Ref).

Dosing: Hepatic Impairment: Adult

Mild to moderate impairment (Child-Pugh classes A and B):

Revatio, Liqrev: No dosage adjustment necessary.

Viagra: Starting dose of 25 mg should be considered.

Severe impairment (Child-Pugh class C):

Revatio, Liqrev: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Viagra: Starting dose of 25 mg should be considered.

Adverse Reactions (Significant): Considerations
Hearing loss

Sudden auditory impairment and hearing loss have occurred. Hearing changes are generally unilateral and may be accompanied by tinnitus and dizziness. A direct relationship between therapy and hearing loss has not been determined (Ref). The potential hearing loss affects high frequencies and is reversible (Ref).

Mechanism: Not clearly established; several proposed mechanisms. May be related to elevated middle inner ear pressure which results from congestion of nasal erectile tissue. Intensification of effects of nitric oxide and/or activation of intracellular cyclic guanosine monophosphate (cGMP) may also contribute (Ref).

Onset: Rapid; most cases occur within 12 to 24 hours (Ref).

Hypotension

Modest decreases in blood pressure (ie, reductions of 7 to 10 mmHg in systolic and 7 mm Hg in diastolic pressure) may occur (Ref). Blood pressure generally normalizes within 6 hours of administration (Ref). Concurrent organic nitrate or guanylate cyclase stimulator therapy may potentiate the vasodilatory effects of sildenafil and produce severe hypotension; use is contraindicated (Ref).

Mechanism: Related to the pharmacologic action; inhibition of phosphodiesterase-5 (PDE-5) activity in the vascular smooth muscle results in vasodilation, which can lead to hypotension (Ref).

Onset: Rapid; decreases in blood pressure generally occur within 1 to 2 hours after administration (Ref).

Risk factors:

• Concomitant medications that either potentiate the vasodilatory effects of sildenafil (eg, alpha-adrenergic antagonists) or increase sildenafil serum concentrations (eg, ritonavir) (Ref)

• Concurrent antihypertensives

• Left ventricular outflow obstruction (eg, aortic stenosis, idiopathic hypertrophic subaortic stenosis)

• Resting hypotension (BP <90/50 mm Hg)

• Fluid depletion

• Autonomic dysfunction

• Hemodynamic instability

Priapism

Painful priapism lasting >4 hours in duration has been reported rarely (Ref).

Mechanism: Related to pharmacologic action; inhibition of phosphodiesterase-5 (PDE-5) activity, which leads to increased accumulation of cyclic guanosine monophosphate (cGMP) in response to release of nitric oxide (Ref).

Onset: Rapid; has occurred shortly after orgasm (Ref).

Risk factors:

• Sildenafil overdose (Ref)

• Concurrent medications that may cause priapism (eg, amitriptyline, nortriptyline, second-generation antipsychotics, trazodone) (Ref)

Visual effects

Visual disturbance (including reversible cyanopsia [blue-tinged vision], photophobia, and blurred vision may occur (Ref). Sudden vision loss in 1 or both eyes may occur and be a sign of nonarteritic anterior ischemic optic neuropathy (NAION); however, a direct relationship has not been determined (Ref). Most visual disturbances are transient (Ref). Cyanopsia, photophobia, and blurred vision typically resolve within 5 hours after discontinuation (Ref). NAION complete resolution may be delayed (weeks to a year) (Ref). Anterior uveitis, macular edema, and retinal artery occlusion have also been reported (Ref).

Mechanism:

• Cyanopsia, photophobia, blurred vision: Dose-related; related to the pharmacologic action. May be a result of minor inhibition of phosphodiesterase-6 (PDE-6) which is expressed in rod and cone photoreceptor cells in the retina (Ref).

• NAION: Not clearly established; may be due to hypoperfusion of ciliary arteries resulting from hypotension (Ref).

Onset: Cyanopsia, photophobia, blurred vision: Rapid; generally occur within 1 to 2 hours after ingestion (Ref). NAION: Varied; hours to months after ingestion (Ref).

Risk factors:

For NAION:

• Low cup-to-disc ratio ("crowded disc") (Ref)

• Older patients (>50 years of age) (Ref)

• Coronary heart disease (Ref)

• Diabetes (Ref)

• Hypertension (Ref)

• Hyperlipidemia (Ref)

• Smoking (Ref)

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

>10%:

Cardiovascular: Flushing (9% to 19%)

Gastrointestinal: Diarrhea (9% to 12%), dyspepsia (3% to 17%)

Nervous system: Headache (16% to 49%)

Neuromuscular & skeletal: Back pain (3% to 13%), limb pain (7% to 15%), myalgia (2% to 14%)

Ophthalmic: Visual disturbance (2% to 11%; including vision color changes, blurred vision, and photophobia)

Respiratory: Epistaxis (2% to 3%; patients with pulmonary arterial hypertension secondary to connective tissue disorder: 13%)

1% to 10%:

Cardiovascular: Angina pectoris (<2%), atrioventricular block (<2%), cardiomyopathy (<2%), chest pain (<2%), ECG abnormality (<2%), edema (<2%), heart failure (<2%), hypotension (<2%), ischemic heart disease (<2%), orthostatic hypotension (<2%), palpitations (<2%), peripheral edema (<2%), shock (<2%), syncope (<2%), tachycardia (<2%)

Dermatologic: Contact dermatitis (<2%), dermal ulcer (<2%), diaphoresis (<2%), exfoliative dermatitis (<2%), pruritus (<2%), skin photosensitivity (<2%), skin rash (2% to 3%), urticaria (<2%)

Endocrine & metabolic: Hyperglycemia (<2%), hypernatremia (<2%), hyperuricemia (<2%), hypoglycemia (<2%), increased thirst (<2%), unstable diabetes (<2%)

Gastrointestinal: Abdominal pain (<2%), colitis (<2%), dysphagia (<2%), esophagitis (<2%), gastroenteritis (<2%), gingivitis (<2%), glossitis (<2%), nausea (2% to 3%), rectal hemorrhage (<2%), stomatitis (<2%), vomiting (<2%), xerostomia (<2%)

Genitourinary: Anorgasmia (<2%), breast hypertrophy (<2%), cystitis (<2%), ejaculatory disorder (<2%), genital edema (<2%), nocturia (<2%), urinary frequency (<2%), urinary incontinence (<2%)

Hematologic & oncologic: Anemia (<2%), leukopenia (<2%)

Hepatic: Abnormal hepatic function tests (<2%)

Hypersensitivity: Facial edema (<2%), hypersensitivity reaction (<2%)

Infection: Herpes simplex infection (<2%)

Nervous system: Abnormal dreams (<2%), absent reflexes (<2%), asthenia (<2%), ataxia (<2%), cerebral thrombosis (<2%), chills (<2%), depression (<2%), dizziness (2% to 4%) (table 1), drowsiness (<2%), falling (<2%), hypertonia (<2%), hypoesthesia (<2%), migraine (<2%), myasthenia (<2%), neuralgia (<2%), neuropathy (<2%), pain (<2%), tremor (<2%), vertigo (<2%)

Sildenafil: Adverse Reaction: Dizziness

Drug (Sildenafil)

Placebo

Dose

Dosage Form

Indication

Number of Patients (Sildenafil)

Number of Patients (Placebo)

4%

2%

50 mg

Tablets

Erectile dysfunction

511

607

3%

2%

100 mg

Tablets

Erectile dysfunction

506

607

3%

2%

25 mg

Tablets

Erectile dysfunction

312

607

2%

1%

N/A

Tablets

Erectile dysfunction

734

725

Neuromuscular & skeletal: Arthritis (<2%), gout (<2%), ostealgia (<2%), osteoarthritis (<2%), rupture of tendon (<2%), synovitis (<2%), tenosynovitis (<2%)

Ophthalmic: Anterior chamber eye hemorrhage (<2%), cataract (<2%), conjunctivitis (<2%), dry eye syndrome (<2%), eye pain (<2%), mydriasis (<2%)

Otic: Auditory impairment (<2%), hearing loss (<2%), otalgia (<2%), tinnitus (<2%)

Respiratory: Asthma (<2%), bronchitis (<2%), dyspnea (<2%), increased bronchial secretions (<2%), increased cough (<2%), laryngitis (<2%), nasal congestion (4% to 9%), pharyngitis (<2%)

Postmarketing:

Cardiovascular: Acute myocardial infarction (Hayat 2007), hypertension, ventricular arrhythmia

Dermatologic: Basal cell carcinoma of skin (Loeb 2015), malignant melanoma (Li 2014; Loeb 2015)

Genitourinary: Hematuria, priapism (Rezaee 2020)

Hematologic & oncologic: Hemorrhage, sickle cell crisis (vaso-occlusive crisis in patients with pulmonary hypertension associated with sickle cell disease) (Machado 2011)

Hepatic: Hepatic failure (Pawar 2022)

Nervous system: Amnesia (transient global), anxiety, cerebral hemorrhage, cerebrovascular hemorrhage, cranial nerve palsy (Lee 2021), psychosis (Shalbafan 2022), seizure (including recurrent seizures), subarachnoid hemorrhage (Adiya 2016), transient ischemic attacks (Morgan 2001)

Ophthalmic: Anterior ischemic optic neuropathy (nonarteritic; NAION) (Campbell 2015), anterior uveitis (Regenold 2021), burning sensation of eyes, diplopia, eye redness, increased intraocular pressure, macular edema (Regenold 2021), retinal artery occlusion (Mahmoud 2022), retinal edema, retinal vascular disease, swelling of eye, vision loss, vitreous detachment, vitreous traction

Respiratory: Pulmonary hemorrhage

Contraindications

Hypersensitivity to sildenafil or any component of the formulation; concurrent use (regularly/intermittently) of organic nitrates in any form (eg, nitroglycerin, isosorbide dinitrate); concomitant use of riociguat (a guanylate cyclase stimulator).

According to the manufacturers of protease inhibitors (atazanavir, darunavir, fosamprenavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir): Concurrent use with a protease inhibitor regimen when sildenafil is used for pulmonary artery hypertension.

Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Canadian labeling: Additional contraindications (not in US labeling):

Viagra: Prior episode of non-arteritic anterior ischemic optic neuropathy (NAION).

Revatio: Prior episode of non-arteritic anterior ischemic optic neuropathy (NAION); concurrent use with potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir); pulmonary hypertension secondary to sickle cell anemia; severe hepatic impairment; recent history of stroke or MI, or life-threatening arrhythmia; coronary artery disease causing unstable angina; severe hypotension (<90/50 mm Hg) at initiation.

Warnings/Precautions

Concerns related to adverse effects:

• Color discrimination: May cause dose-related impairment of color discrimination. Use caution in patients with retinitis pigmentosa; a minority have genetic disorders of retinal phosphodiesterases (no safety information available).

• Hypotension: Caution patients that concurrent use of alcohol, particularly in larger quantities, may increase the risk for orthostatic hypotension, dizziness, tachycardia, and headache. Recommend limiting any alcohol use to smaller quantities and refraining from such combined use as possible.

Disease-related concerns:

• Anatomical penis deformation: Use with caution in patients with anatomical deformation of the penis (angulation, cavernosal fibrosis, or Peyronie disease).

• Bleeding disorders: Use with caution in patients with bleeding disorders; safety has not been established. In vitro studies have suggested a decreased effect on platelet aggregation.

• Cardiovascular disease: Use with caution in patients with hypotension (<90/50 mm Hg); uncontrolled hypertension (>170/110 mm Hg); life-threatening arrhythmias, stroke or MI within the last 6 months; cardiac failure or coronary artery disease causing unstable angina; safety and efficacy have not been studied in these patients. Use caution in patients with left ventricular outflow obstruction (eg, aortic stenosis). Patients should be hemodynamically stable prior to initiating therapy at the lowest possible dose. There is a degree of cardiac risk associated with sexual activity; therefore, health care providers should consider the cardiovascular status of their patients prior to initiating any treatment for erectile dysfunction.

• Conditions predisposing to priapism: Use with caution in patients who have conditions which may predispose them to priapism (sickle cell anemia, multiple myeloma, leukemia). All patients should be instructed to seek immediate medical attention if erection persists >4 hours.

• Hepatic impairment: Use with caution in patients with hepatic impairment; dose adjustment may be required.

• Peptic ulcer disease: Use with caution in patients with active peptic ulcer disease; safety has not been established.

• Pulmonary arterial hypertension: Sudden cessation of sildenafil monotherapy could result in an exacerbation of pulmonary arterial hypertension (PAH). Efficacy in adult patients determined through short-term (12 to 16 week) studies; safety of longer-term use is unclear. A long-term use trial in pediatric patients showed increased mortality in the higher dose groups (20 to 80 mg [depending upon weight] 3 times per day) after 2 years of use, which was related to disease progression (Barst 2012; Barst 2014; manufacturer's labeling).

• Pulmonary veno-occlusive disease: Use in patients with pulmonary veno-occlusive disease (PVOD) is not recommended (has not been studied); if pulmonary edema occurs when treating PAH, consider the possibility of PVOD.

• Renal impairment: Use with caution in patients with renal impairment; dose adjustment may be needed.

• Sickle cell anemia: Treatment of pulmonary hypertension with sildenafil in this patient population may lead to more hospitalizations for management of vaso-occlusive crises. The effectiveness and safety of sildenafil have not been established in pulmonary hypertension secondary to sickle cell disease.

Concurrent drug therapy issues:

• Nitrates: Use of sildenafil is contraindicated in patients currently taking nitrate preparations. However, when nitrate administration becomes medically necessary, American College of Cardiology/American Heart Association guidelines support administration of nitrates only if 24 hours have elapsed after use of sildenafil (ACC/AHA [Amsterdam 2014]; ACCF/AHA [O'Gara 2013]); may need to wait longer than 24 hours in patients with renal or hepatic dysfunction.

Special populations:

• Older adult: Use with caution; dose adjustment may be required.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.

• Suspension: Oral suspensions may be available in multiple concentrations (commercially available: 10 mg/mL; extemporaneous preparation: 2.5 mg/mL); dosing should be presented in mg of sildenafil; use extra precaution when verifying product formulation and calculation of dose volumes.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Revatio: 10 mg/12.5 mL (12.5 mL)

Generic: 10 mg/12.5 mL (12.5 mL)

Suspension, Oral, as citrate:

Liqrev: 10 mg/mL (122 mL) [contains sodium benzoate]

Suspension Reconstituted, Oral:

Revatio: 10 mg/mL (112 mL) [contains sodium benzoate; grape flavor]

Generic: 10 mg/mL (112 mL)

Tablet, Oral:

Revatio: 20 mg

Viagra: 25 mg, 50 mg, 100 mg [contains fd&c blue #2 (indigo carm) aluminum lake]

Generic: 20 mg, 25 mg, 50 mg, 100 mg

Generic Equivalent Available: US

May be product dependent

Pricing: US

Solution (Revatio Intravenous)

10 mg/12.5 mL (per mL): $24.83

Solution (Sildenafil Citrate Intravenous)

10 mg/12.5 mL (per mL): $17.60

Suspension (Liqrev Oral)

10 mg/mL (per mL): $18.64

Suspension (reconstituted) (Revatio Oral)

10 mg/mL (per mL): $109.00

Suspension (reconstituted) (Sildenafil Citrate Oral)

10 mg/mL (per mL): $1.07 - $87.94

Tablets (Revatio Oral)

20 mg (per each): $70.69

Tablets (Sildenafil Citrate Oral)

20 mg (per each): $19.00 - $22.05

25 mg (per each): $0.11 - $66.46

50 mg (per each): $0.11 - $66.46

100 mg (per each): $0.11 - $66.46

Tablets (Viagra Oral)

25 mg (per each): $99.92

50 mg (per each): $99.92

100 mg (per each): $99.92

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:

Revatio: 10 mg/12.5 mL (12.5 mL)

Tablet, Oral:

Revatio: 20 mg

Viagra: 25 mg, 50 mg, 100 mg [contains fd&c blue #2 (indigo carm) aluminum lake]

Generic: 20 mg, 25 mg, 50 mg, 100 mg

Extemporaneous Preparations

Note: Commercial oral suspension is available (10 mg/mL).

2.5 mg/mL oral suspension

A 2.5 mg/mL sildenafil citrate oral suspension may be made with tablets and either a 1:1 mixture of methylcellulose 1% and simple syrup NF or a 1:1 mixture of Ora-Sweet and Ora-Plus. Crush thirty sildenafil 25 mg tablets (Viagra) in a mortar and reduce to a fine powder. Add small portions of chosen vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to almost 300 mL; transfer to a graduated cylinder, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 300 mL. Store in amber plastic bottles and label "shake well". Stable for 90 days at room temperature or refrigerated.

Nahata MC, Morosco RS, and Brady MT. Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children. Am J Health-Syst Pharm. 2006;63(3):254-257.16434784
Administration: Pediatric

Oral: Revatio: Note: Oral suspensions may be available in multiple concentrations (commercially available: 10 mg/mL; extemporaneous preparation: 2.5 mg/mL); use extra precaution when verifying product formulation and calculation of dose volumes. The 2 mL oral syringe included with the 10 mg/mL oral suspension only provides measurements for fixed doses of 5 mg and 20 mg; for patients not receiving either of these fixed doses, an appropriate-size calibrated oral syringe should be dispensed.

Administer doses at least 4 to 6 hours apart; may be administered without regard to meals; shake oral suspension well prior to use.

IV: Revatio:

Neonates:

Continuous IV infusion:

Loading dose: Usually administered over 3 hours (Ref).

Continuous IV infusion: Administer as a continuous IV infusion with the use of an infusion pump.

Intermittent IV infusions: Infusion time variable; infuse over 1 hour, longer infusion times are commonly used to minimize risk of hypotension; reported infusion times range: 15 minutes to 3 hours (Ref).

Infant, Children, and Adolescents: In clinical trials, loading dose was administered as a bolus over 5 minutes, followed by a continuous IV infusion (Ref).

Administration: Adult

Oral:

Revatio, Liqrev: Administer doses with or without food. Shake oral suspension well for ≥10 seconds before administering each dose; do not mix with any other medication or additional flavoring agent. Administer with an accurate measuring device (eg, calibrated oral syringe).

Viagra: Administer with or without food 30 minutes to 4 hours before sexual activity

IV: Revatio: Administer as an IV bolus.

Storage/Stability

Tablets/injection: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F).

Oral suspension:

Revatio: Store unreconstituted powder below 30°C (86°F); protect from moisture. Store reconstituted oral suspension below 30°C (86°F) or at 2°C to 8°C (36°F to 46°F). Do not freeze. Discard unused product 60 days after reconstitution.

Liqrev: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F). Discard unused product 90 days after opening bottle.

Use

Treatment of WHO Group I pulmonary arterial hypertension (PAH) (Revatio: FDA approved in ages ≥1 year and adults; Liqrev: FDA approved in adults); treatment of erectile dysfunction (Viagra: FDA approved in male adults). Has also been used for treatment of persistent pulmonary hypertension of the newborn (PPHN), treatment of bronchopulmonary dysplasia (BPD) associated pulmonary hypertension, facilitation of weaning from nitric oxide (ie, to attenuate rebound effects after discontinuing inhaled nitric oxide), and secondary pulmonary hypertension following cardiac surgery.

Medication Safety Issues
Sound-alike/look-alike issues:

Revatio may be confused with ReVia, Revonto

Sildenafil may be confused with silodosin, tadalafil, vardenafil

Viagra may be confused with Allegra, Vaniqa

Metabolism/Transport Effects

Substrate of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alcohol (Ethyl): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. Risk C: Monitor therapy

Alpha1-Blockers (Nonselective): Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Alpha1-Blockers (Nonselective). Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended. Risk D: Consider therapy modification

Alpha1-Blockers (Uroselective): May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. Risk C: Monitor therapy

Alprostadil: Phosphodiesterase 5 Inhibitors may enhance the adverse/toxic effect of Alprostadil. Risk X: Avoid combination

Amyl Nitrite: Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Amyl Nitrite. Risk X: Avoid combination

Blood Pressure Lowering Agents: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Bosentan: May decrease the serum concentration of Sildenafil. Sildenafil may increase the serum concentration of Bosentan. Management: When sildenafil is used for treatment of pulmonary arterial hypertension (PAH), coadministration of sildenafil and bosentan is not recommended. Otherwise, monitor for reduced sildenafil efficacy if combined with bosentan. Risk D: Consider therapy modification

Ciprofloxacin (Systemic): May increase the serum concentration of Sildenafil. Risk C: Monitor therapy

Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk C: Monitor therapy

Cobicistat: May increase the serum concentration of Sildenafil. Management: Use of cobicistat and sildenafil for the treatment of PAH is contraindicated. If using sildenafil for the treatment of erectile dysfunction, limit the sildenafil dose to 25 mg and do not use more frequently than every 48 hours. Risk D: Consider therapy modification

CYP3A4 Inducers (Moderate): May decrease the serum concentration of Sildenafil. Risk C: Monitor therapy

CYP3A4 Inducers (Strong): May decrease the serum concentration of Sildenafil. Risk C: Monitor therapy

CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Sildenafil. Risk C: Monitor therapy

CYP3A4 Inhibitors (Strong): May increase the serum concentration of Sildenafil. Management: Use of sildenafil for pulmonary arterial hypertension (PAH) should be avoided with strong CYP3A4 inhibitors. When used for erectile dysfunction, consider using a lower starting dose of 25 mg and monitor patients for sildenafil toxicities. Risk D: Consider therapy modification

Dapoxetine: May enhance the orthostatic hypotensive effect of Phosphodiesterase 5 Inhibitors. Risk X: Avoid combination

Erythromycin (Systemic): May increase the serum concentration of Sildenafil. Management: For pulmonary arterial hypertension, no dose adjustment required. For erectile dysfunction, consider using a lower starting dose of 25 mg in patients who are also taking erythromycin. Monitor patients for sildenafil toxicities when combined. Risk D: Consider therapy modification

Etravirine: May decrease the serum concentration of Phosphodiesterase 5 Inhibitors. Risk C: Monitor therapy

Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Risk X: Avoid combination

Grapefruit Juice: May increase the serum concentration of Sildenafil. Risk C: Monitor therapy

Lenacapavir: May increase the serum concentration of Sildenafil. Management: For pulmonary arterial hypertension, no dose adjustment required. For erectile dysfunction, use a lower starting dose of 25 mg in patients who are also taking lenacapavir. Monitor patients for sildenafil toxicities when combined. Risk D: Consider therapy modification

Lorcaserin (Withdrawn From US Market): May enhance the adverse/toxic effect of Phosphodiesterase 5 Inhibitors. Specifically, the risk of developing priapism may be increased. Risk C: Monitor therapy

Molsidomine: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. Risk X: Avoid combination

Nitroprusside: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Nitroprusside. Risk X: Avoid combination

Phosphodiesterase 5 Inhibitors: May enhance the adverse/toxic effect of other Phosphodiesterase 5 Inhibitors. Risk X: Avoid combination

Protease Inhibitors: May increase the serum concentration of Sildenafil. Management: Use of protease inhibitors and sildenafil for the treatment of PAH is contraindicated. If using sildenafil for the treatment of erectile dysfunction, limit the sildenafil dose to 25 mg and do not use more frequently than every 48 hours. Risk D: Consider therapy modification

Riociguat: Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Riociguat. Risk X: Avoid combination

Sapropterin: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. Risk C: Monitor therapy

Simeprevir: May increase the serum concentration of Phosphodiesterase 5 Inhibitors. Risk C: Monitor therapy

Vasodilators (Organic Nitrates): Phosphodiesterase 5 Inhibitors may enhance the vasodilatory effect of Vasodilators (Organic Nitrates). Risk X: Avoid combination

Vericiguat: May enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. Risk X: Avoid combination

Food Interactions

Grapefruit juice may increase serum levels/toxicity of orally administered sildenafil. Management: Monitor for increased effects/toxicity with concomitant oral use.

Pregnancy Considerations

Sildenafil was shown to cross the placenta in an ex vivo placenta perfusion study (Russo 2018).

Because sildenafil causes vasodilation in the uterus, it is currently under study for various obstetric uses (Dunn 2016; Dunn 2017; Groom 2019; Maged 2018; Maher 2019; Pels 2017; Sharp 2018). However, due to adverse events in the newborn observed using preliminary data from a study evaluating sildenafil for fetal growth restriction, use of sildenafil in pregnant women outside of a controlled clinical study is not currently recommended (Groom 2018; Levin 2019).

Information related to the use of sildenafil for the treatment of pulmonary arterial hypertension (PAH) in pregnant women is limited (Cartago 2014; Hsu 2011; Lim 2019; Wollein 2016). Untreated PAH in pregnancy increases the risk for heart failure, stroke, preterm delivery, and maternal/fetal death. Women with PAH are encouraged to avoid pregnancy (McLaughlin 2009; Taichman 2014).

Monitoring Parameters

Heart rate, blood pressure, oxygen saturation, PaO2, oxygenation index.

Mechanism of Action

Erectile dysfunction: Does not directly cause penile erections but affects the response to sexual stimulation. The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE-5), which is responsible for degradation of cGMP in the corpus cavernosum; when sexual stimulation causes local release of NO, inhibition of PDE-5 by sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum; at recommended doses, it has no effect in the absence of sexual stimulation.

Pulmonary arterial hypertension (PAH): Inhibits phosphodiesterase type 5 (PDE-5) in smooth muscle of pulmonary vasculature where PDE-5 is responsible for the degradation of cyclic guanosine monophosphate (cGMP). Increased cGMP concentration results in pulmonary vasculature relaxation; vasodilation in the pulmonary bed and the systemic circulation (to a lesser degree) may occur.

Pharmacokinetics (Adult Data Unless Noted)

Onset of action: Erectile dysfunction: ~60 minutes.

Peak effect: Decrease blood pressure: Oral: 1 to 2 hours.

Duration: Erectile dysfunction: 2 to 4 hours; Decrease blood pressure: <8 hours.

Absorption: Rapid; slower with a high-fat meal; tablet and suspension are bioequivalent.

Distribution: Distributes into tissues.

Vd total:

Term neonates: 19.8 to 22.4 L (Mukherjee 2009; Rhee 2022).

Vdss: Adults: 105 L.

Protein binding, plasma:

Term neonates: Sildenafil: 93.9% ± 2.5%; N-desmethyl metabolite: 92% ± 3% (Mukherjee 2009).

Adults: Sildenafil and N-desmethyl metabolite: ~96%.

Metabolism: Hepatic via CYP3A4 (major) and CYP2C9 (minor route); major metabolite (UK-103320 or desmethylsildenafil) is formed via N-desmethylation pathway and has 50% of the potency of sildenafil.

Bioavailability: Oral: Mean: 41%; range: 25% to 63%; may be higher in patients with PAH compared to healthy volunteers; Note: A 10 mg dose of the injection is predicted to have an effect equal to a 20 mg oral dose taking into consideration the parent drug and active metabolite.

Half-life elimination:

Sildenafil: Terminal:

Term neonates (Mukherjee 2009):

PNA 1 day: 55.9 hours.

PNA 7 days: 47.7 hours.

Adults: 4 hours.

Active N-desmethyl metabolite: Terminal:

Neonates: 11.9 hours (Mukherjee 2009).

Adults: 4 hours.

Time to peak: Oral: Fasting: 30 to 120 minutes (median 60 minutes); delayed by 60 minutes with a high-fat meal.

Excretion: Feces (~80%, as metabolites); urine (~13%).

Clearance: Decreased in patients with hepatic cirrhosis or severe renal impairment; clearance may be lower in patients with PAH compared to normal volunteers. Sildenafil clearance in newborns is significantly decreased compared to adults, but approaches adult (allometrically scaled) values by the first week of life (Mukherjee 2009). Clearance of N-desmethyl active metabolite is decreased in patients with severe renal impairment.

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Severe renal impairment is associated with increased plasma levels.

Hepatic function impairment: Hepatic impairment is associated with increased plasma levels.

Older adult: Age 65 years or older is associated with increased plasma levels.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Bluvisa | Erecta | Eregra | Fallah | Maestro | Sife | Silafil | Sildomax | Siler | Tournes | Viagra | Viatuff | Vigalife | Vilna | Wafi | Zed;
  • (AR) Argentina: 4 x 4 | Almaximo | Anaus | Bifort | Cagno | Egomax | Erectol | Expit | Falic | File | Firmel | Gimonte Sildenafil | Hepil | Incresil | Juvigor | Labsamax | Lumix | Magnus | Magnus Flash | Maxdosa | Maxdosa hap | Nexofil | Nitro | Openvas | Oxivital | Paramen | Pluspen | Segurex | Sildefil | Sildenafil | Sildenafil Hlb | Sildenafil Ilab | Sildenafil sandoz | Sildenafil Vannier | Super O | Tecnomax | Verum | Viagra | Vimax | Vimax flash | Virilon | Viripotens | Vitarfil | Vorst;
  • (AT) Austria: Cilafil | Granpidam | Pulmolan | Pulmopresil | Revatio | Sildenafil | Sildenafil 1 A Pharma | Sildenafil A Med | Sildenafil Actavis | Sildenafil Genericon | Sildenafil pfizer | Sildenafil ratiopharm | Sildenafil sandoz | Sildenafil stada | Sildenafil teva | Sildenafil viatris | Viagra | Vizarsin;
  • (AU) Australia: Apo sildenafil | Apo sildenafil pht | Avigra | Cm sildenafil | Ernafil | Kopigra dr | Lisan | Mevia | Noumed sildenafil | Pharmacor sildenafil | Revatio | Silaran | Sildaccord | Sildanil | Sildenafil Actavis | Sildenafil an | Sildenafil an pht | Sildenafil aspen | Sildenafil drla | Sildenafil drx | Sildenafil gh | Sildenafil hx | Sildenafil lupin | Sildenafil medis | Sildenafil pfizer | Sildenafil ranbaxy | Sildenafil rbx | Sildenafil sandoz | Sildenafil watson | Sildocor | Silerec | Tw sildenafil | Vasafil | Vedafil | Viagra | Wafesil | Zelnafil;
  • (BD) Bangladesh: Adegra | Aggra | Danafil | Edegra | Enegra | Enigma | Enjofil | Fulfeel | Immense | Niagra | Novagra | Panagra | SB sild | Silagra | Silfil | V gra | Viamax | Vigorex;
  • (BE) Belgium: Balcoga | Revatio | Sildenafil apotex | Sildenafil eg | Sildenafil mylan | Sildenafil sandoz | Sildenafil teva | Sildenon | Verventi | Viagra | Vizarsin;
  • (BF) Burkina Faso: Asmoforce | Erekta | Giagra | Kamagra | Plaevz | Powergra | Rigide | Sidegra | Viagra;
  • (BG) Bulgaria: Balcoga | Ecriten | Eroton | Revatio | Silden | Sildenafil | Sildenafil Medana | Sildenafil ratiopharm | Sildenafil stada | Silegria | Sinegra | Taxier | Viagra | Vigrande | Vizarsin;
  • (BR) Brazil: Ah zul | Blupill | Citrato de sildenafila | Dejavu | Escitan | Prilo | Revatio | Sildara | Sollevare | Suvvia | Tantrix | Vasifil | Viagra | Viasil | Videnfil | Virineo;
  • (CH) Switzerland: Revatio | Sildenafil Actavis | Sildenafil axapharm | Sildenafil helvepharm | Sildenafil mepha | Sildenafil nobel | Sildenafil PAH Mepha | Sildenafil pah mylan | Sildenafil pah spirig hc | Sildenafil pfizer | Sildenafil sandoz | Sildenafil spirig hc | Sildenax | Viagra;
  • (CI) Côte d'Ivoire: Asmoforce | Erector | Erefil | Giagra | Kifaru | Plaevz | Plasir | Rigide | Sidegra | Silagra | Silnafil | Viagra | Viatec | Vigofeel | Vigorex | Virectil;
  • (CL) Chile: Alfin | Dirtop | Disilden | Erosfil | Esantop | Exifol | Falom | Helpin | Hetagra | Lifter | Novalif | Plusefec | Ripol | Seler | Siafil | Viagra | Vigorex;
  • (CN) China: Jin ge | Viagra;
  • (CO) Colombia: Afrosyn | Aleos | Biflace | Brios komplet man | Chaz | Ciaplen | Diserec | Disfureck | Dyna sex | Efeza | Ejertol | Elebra | Eleve | Erassin | Erecfor | Erefil | Erilin | Eroxim | Ex max | Fulerec | Gelpin | Gelpin fast | Hormotone | Lucidril | Maxeril | Montriex | Parolex | Placidium | Placidum | Plenifil | R sione | Renafil | Rociblue | Sentilux | Sildafil | Sildelife | Sildenafil | Sildenafil citrato | Sildenafil mk | Sildenafilo | Sildufi | Sindevalfir | Sinfer | Sinota | Tranky | Varofil | Viagra | Viagra odt | Vifortil | Vigradina | Vimax | Vintix | Vyasil forte | Vygrand;
  • (CR) Costa Rica: Ero plus;
  • (CZ) Czech Republic: Amfidor | Balcoga | Ecriten | Granpidam | Grasil | Modrasil | Mysildecard | Olvion | Revatio | Silaxa | Sildenafil accord | Sildenafil Actavis | Sildenafil apotex | Sildenafil Aurovitas | Sildenafil Medana | Sildenafil medreg | Sildenafil mylan | Sildenafil pfizer | Sildenafil sandoz | Sildenafil teva | Silfeldrem | Viagra | Vigrande | Vizarsin;
  • (DE) Germany: Arifil | Duraviril | Ereq | Granpidam | Mysildecard | Revatio | Sildaristo | Sildegra | Sildehexal | Sildenafil | Sildenafil 1a pharma | Sildenafil Actavis | Sildenafil Aliud | Sildenafil aristo pah | Sildenafil aurobindo | Sildenafil axunio | Sildenafil Basics | Sildenafil beta | Sildenafil biomo | Sildenafil FairFarma | Sildenafil Hennig | Sildenafil heumann | Sildenafil holsten | Sildenafil Hormosan | Sildenafil macleods | Sildenafil Neuraxpharm | Sildenafil pfizer | Sildenafil puren pah | Sildenafil ratiopharm | Sildenafil stada | Sildenafil sun | Sildenafil Uropharm | Sildenafil zentiva | Silnerton | Sinegra | Valedonis | Viagra | Vizarsin;
  • (DK) Denmark: Vizarsin;
  • (DO) Dominican Republic: Erec-F | Eroxim | Gerosex | Jumper | Levapen | Patrex | Pronac | Revive | Silden | Sildenafil | Sildenafil citrato | Sildenafil if | Spetrum | Veradur | Vergadur | Viafran | Viagra;
  • (EC) Ecuador: Almaximo | Caverta | Equis x | Equis x da | Erecstar | Erectron | Erekctil | Erotil | Five films | Fogo | Funcional | Max | Medovigor | Potencil | Rezum | Ripol | Sildenafil | Sildenafil mk | Sildenafilo | Sutra | Trepol | Venux | Verec | Viagra | Vigorex | Vigoril | Xex;
  • (EE) Estonia: Granpidam | Mysildecard | Olvion | Revatio | Sildenafil accord | Sildenafil Actavis | Sildenafil Medana | Sildenafil pfizer | Sildenafil ratiopharm | Sildenafil sandoz | Sildenafil teva | Silungo | Viagra | Vigrande | Vizarsin;
  • (EG) Egypt: Brilliant | Ectagor | Erec | Erecton | Ezequel | Kemagra | Napifit | Oragawell | Orgodenafil | Respatio | Satenafil | Silanil | Sildatrona | Sildava | Silden | Sildenafil mylan | Sildinax | Silvagra | Silvigo | Spika | Stimu max | V gone | Veora | Vetoyagra | Viagra | Viavag | Vigadol | Vigor | Vigoran | Vigorex | Virecta;
  • (ES) Spain: Balcoga | Dragul | Fexion | Galotam | Granpidam | Mysildecard | Oximum | Psiliber | Revatio | Sildenafilo Actavis | Sildenafilo Almus | Sildenafilo Apotex | Sildenafilo aristo | Sildenafilo bluefish | Sildenafilo cinfa | Sildenafilo cinfamed | Sildenafilo combix | Sildenafilo dr. reddys | Sildenafilo Kern Pharma | Sildenafilo krka | Sildenafilo Mylan | Sildenafilo Normon | Sildenafilo pensa | Sildenafilo Ratiopharm | Sildenafilo Sandoz | Sildenafilo Stada | Sildenafilo tarbis | Sildenafilo TecniGen | Sildenafilo teva | Sildenafilo zentiva | Viagra | Vizarsin | Zuandol;
  • (ET) Ethiopia: Akigra | Kamagra | Seedios | Seldipro | Sildenafil | Temptcure | Viagra | Vigeranafil | Virecta | Zimagra;
  • (FI) Finland: Balcoga | Granpidam | Mysildecard | Orisild | Revastad | Revatio | Sildenafil accord | Sildenafil Actavis | Sildenafil aspen | Sildenafil orifarm | Sildenafil orion | Sildenafil pfizer | Sildenafil ratiopharm | Sildenafil sandoz | Sildenafil stada | Sildenafil teva | Viagra | Vizarsin;
  • (FR) France: Cetinor | Granpidam | Mysildecard | Revatio | Sildenafil accord | Sildenafil Actavis | Sildenafil almus | Sildenafil arrow | Sildenafil biogaran | Sildenafil cristers | Sildenafil eg | Sildenafil mylan | Sildenafil pfizer | Sildenafil ranbaxy | Sildenafil sandoz | Sildenafil teva | Sildenafil zentiva | Sildenafil zydus | Viagra | Vizarsin;
  • (GB) United Kingdom: Aronix | Eropid | Granpidam | Liberize | Mysildecard | Revatio | Sildenafil | Sildenafil bristol lab | Sildenafil hameln | Sildenafil teva | Viagra | Viagra connect | Vizarsin | Zamantos;
  • (GR) Greece: Blugral | Bluozi | Dialex | Licosil | Olvion | Revatio | Sildenafil Actavis | Sildenafil heremco | Sildenafil liconsa | Sildenafil mylan | Sildenafil pfizer | Sildenafil teva | Sildenafil/bausch | Sildenafil/gerolymatos | Sildenafil/lyofin | Sildenafil/Sandoz | Sildenafil/vianex | Strondem | Viagra | Vizarsin;
  • (HK) Hong Kong: Elonza | Erecor 100 | Erecto | Ericfil | Ernafil | Finegra | Hippigra | Maxigra | Pms sildenafil R | Powergra | Revatio | Silagra | Silden | Sildenafil stada | Silvie | Sinafil | Sliting | Tigerfil | Veligo | Viagra | Vilakra | Willmon | Zygra;
  • (HR) Croatia: Dinamico | Granpidam | Revatio | Sildenafil pliva | Tornetis | Viagra | Vizarsin;
  • (HU) Hungary: Ecriten | Erasilton | Revatio | Sildegra | Sildenafil mylan | Sildenafil pfizer | Sildenafil Pharmacenter | Sildenafil rivopharm | Sildenafil sandoz | Sildenafil teva | Silderec | Vegamac | Viagra | Viandros | Vigrande | Vizarsin;
  • (ID) Indonesia: Caprenafil | Emposil | Ericfil | Legra | Revatio | Sanbenafil | Sildenafil | Topgra | Viagra | Viajoy | Vimax;
  • (IE) Ireland: Blugral | Granpidam | Mysildecard | Revatio | Sidena | Silcarfil | Sildenafil | Viagra | Viagra connect | Vizarsin;
  • (IL) Israel: Tarim | Viagra;
  • (IN) India: 1-2-3 | 11PM | Adams delite | Alsigra | Androz | Assurans | Caverta | Dasutra x | Double force | Dr.x | Edegra | Edysafe | Enthusia | Erec | Eriacta | Erix | Eunice | Exygra | Fildena | Fire | Hernafil | Instarise | Intagra | Integra | Joshila | Juan | Kamagra | Lupigra | Lyga | Macsutra | Manegra | Manforce | Maxbull | Niagra | Nyte | Omnigra | Pah | Pefomax | Penegra | Piyagra | Playgard | Primiwal s | Progra | Pulmoday | Rezum | Seleg | Seregra | Shefill | Sil xt | Silagra | Sildegat | Suhagra | Tonite | Ulti-mate | Ultimate | Unigra | Uplift | Vasosure | Vigora | Vigreks | Viraha | Virecta | Vistagra | Vogira | Volo | Wavegra | Wingora | Xplod-s | Zeagra | Zenegra | Zestogra;
  • (IQ) Iraq: Samagra;
  • (IT) Italy: Azurvig | Balcoga | Blugral | Granpidam | Mendie | Mysildecard | Prelud | Rabestrom | Revatio | Sildenafil | Sildenafil abc | Sildenafil accord | Sildenafil Actavis | Sildenafil almus | Sildenafil aristo | Sildenafil aurobindo | Sildenafil caber | Sildenafil doc | Sildenafil dr. reddy's | Sildenafil eg | Sildenafil germed | Sildenafil macleods | Sildenafil ranbaxy | Sildenafil sandoz | Sildenafil tecnigen | Sildenafil zentiva | Siler | Viagra | Viagra farmed | Vizarsin | Zakfil;
  • (JO) Jordan: Adenafil | Aphrodil | Bluvisa | Klick | Viagra | Vigain | Vigro | Vonta | Zed | Zoltan;
  • (JP) Japan: Revatio | Sildenafil | Sildenafil towa | Sildenafil vi | Viagra;
  • (KE) Kenya: Antigara | Aphrodis | Astagra | Celitra | Cenforce | Comit | Cosagra | Degra | Enogra | Evagra | Evoke | Filaven | Giagra | Gomore | Hot | Kamagra | Kifaru | Manforce | Mtm | Mygra | Negax | Nelgra | Njoi | Plamore | Powergra | Seldipro | Seregra | Sforce | Siloflam | Synogra | Tiagra | Vega | Vegon | Viagra | Viatuff | Vigorex | Vionex | Zedgra | Zegra;
  • (KR) Korea, Republic of: Agnafil | Allat's | Balgria | Bamirac | Bizela | Bogra | Candegra | Cengla | Confidence | Daewoongbio sildenafil | Denargra | Edforce | Erenafil | For mr. | Forte v | Fortera | Freegra | Freestin | Freeya | H U | Happigra | Hecate | Heragra | Maxigra | Maxigra odt | Navigra | Newbigra | Nurigra | Obaram | Padenafil | Pahtension | Palpal | Pristine | Progra | Revatio | Rufian | Sengla | Sildenafil | Silvie | Syrius | Thor s | Unigra | Valtax | Varofil | Viagra | Viaris | Vistra | Viya | Zygra;
  • (KW) Kuwait: Maestro | Revatio | Viagra;
  • (LB) Lebanon: Aphrodil | Degra | Erector | Please | Segurex | Seldan | Sildenafil Arrow Lab | Tournes | Vega Plus | Viadis | Viagra | Vigoram | Vigro | Virecta | Vonta;
  • (LT) Lithuania: Ecriten | Gladix | Granpidam | Mysildecard | Olvion | Revatio | Sildenafil accord | Sildenafil Actavis | Sildenafil Medana | Sildenafil ratiopharm | Sildenafil sandoz | Sildenafil Teva Pharma | Sildenafil torrent | Silungo | Taxier | Viagra | Vigrande | Vizarsin;
  • (LU) Luxembourg: Sildehexal | Sildenafil apotex | Sildenafil eg | Sildenafil ratiopharm | Sildenon | Verventi | Viagra;
  • (LV) Latvia: Ecriten | Granpidam | Mysildecard | Olvion | Revatio | Sildenafil accord | Sildenafil Actavis | Sildenafil ratiopharm | Sildenafil sandoz | Sildenafil teva | Silungo | Viagra | Vizarsin;
  • (MA) Morocco: Erector | Kamagra | Revatio | Sildenafil | Viagra | Viarect | Vibrex | Vigorex | Vimax | Zoltan;
  • (MT) Malta: Vizarsin;
  • (MX) Mexico: Actiraam | Apodefil | Bisglow | Blitsons | Bullenza | Delectat orm | Dionixol | Edegra | Figral | Forzandros | G4 | Go | Lerk | M force | Maxifort Zimax | Mazzogran | Ormokron | Orthiox | Osidea gl | Osideagl | Patrex | Revathio | Revatio | Rindec quim | Sildenafil | Sildenafil accord | Sildenafil lilly | Sindebax | Tomirat | Trectyl | Vegron | Viagra | Viagra odt | Viather by corne | Vitanafil | Voguel | Ysus;
  • (MY) Malaysia: Androz | Avogra | Axcel sildenafil | Caverta | Edyfil | Elonza | Giagra | Iqnyde | Maxefil | Revatio | Sildegra | Viagra;
  • (NG) Nigeria: Agedol | Bleorga | Exxgraa | Garyagra | Global young sildenafil citrate | Homograe | Homotex | Hygra | Intracell's sildenafil citrate | Jozogra | Jubigra | Kifaru | Koyogra | Lemdafil | Liricon sildenafil | Manimax | Njoi | Nubbaxx | Oliga | Penegra | Saodafil | Sd sildenafil | Shree manup | Sigra | Silamac | Sildenafil | Sildigra | Simbagra | Sofigor | Stayon | Sun filup | Taiga | Tiveka | Topigra | Veez | Vegaasia | Vennat | Vigabase | Vigafit | Welgamax | Wingora | Wooga | Zoga;
  • (NL) Netherlands: Balcoga | Granpidam | Mysildecard | Revatio | Sildenafil | Sildenafil accord | Sildenafil Actavis | Sildenafil apotex | Sildenafil mylan | Sildenafil sandoz | Sildenafil xiromed | Viagra | Vizarsin;
  • (NO) Norway: Granpidam | Mysildecard | Orisild | Revatio | Sildenafil Actavis | Viagra;
  • (NZ) New Zealand: Avigra | Noumed sildenafil | Revatio | Silagra | Silvasta | Vedafil | Viagra;
  • (PE) Peru: Agrafil | Akabar | Alclimax | Atizalo max | Blue up | Caverta | Circulass | Circulass rapid | Ejertol | Elevamax | Erectol Plus | Erevit | Free lover | Helpin | Lyons | Pasuma nf | Penon | Plenylife | Porte | Pramil | Pramil forte | Rhocamass | Ripol | Sextreme | Sildamek | Sildecin | Sildemax | Silden up | Sildenafil | Sildenafilo | Sildenal | Sildenazinn | Silderec | Sildex | Sildexcel | Silfil | Sitrepa | Sutra | Venux | Viagra | Viagra odt | Vialza | Vimax;
  • (PH) Philippines: Ambigra | Andros | Erefil | Kohagra | Penegra | Plefil | Pronafil | Sildenafil | Sildora | Spiagra | Tigerfil | Viagra | Virtus | Vivax | Zenera | Zilden;
  • (PL) Poland: Actigra | Ecriten | Falsigra | Granpidam | Lekap | Maxigra max | Maxon | Maxon active | Maxon forte | Princex | Remidia | Revatio | Silandyl | Silcontrol | Silden | Sildenafil accord | Sildenafil Actavis | Sildenafil apotex | Sildenafil Aurovitas | Sildenafil axxon | Sildenafil bluefish | Sildenafil espefa | Sildenafil genoptim | Sildenafil Medana | Sildenafil medical valley | Sildenafil medreg | Sildenafil ranbaxy | Sildenafil ratiopharm | Sildenafil sandoz | Sildenafil symphar | Sildenafil teva | Sildenafil vitama | Sildenafil zentiva | Sildenafilum farmacom | Silungo | Valinger | Valinger forte | Viagra | Viagra connect max | Vigrande | Vizarsin;
  • (PR) Puerto Rico: Revatio | Sildenafil | Viagra;
  • (PT) Portugal: Amfidor | Blugral | Erepry | Granpidam | Mysildecard | Revatio | Sildenafil | Sildenafil Actavis | Sildenafil alter | Sildenafil aurobindo | Sildenafil Aurovitas | Sildenafil azevedos | Sildenafil bluefish | Sildenafil Ciclum | Sildenafil farmoz | Sildenafil gp | Sildenafil Jaba | Sildenafil krka | Sildenafil labesfal | Sildenafil mylan | Sildenafil odipe | Sildenafil osir | Sildenafil Pentafarma | Sildenafil pfizer | Sildenafil pharmakern | Sildenafil pinopharma | Sildenafil ratiopharm | Sildenafil reconir | Sildenafil sandoz | Sildenafil Sidefarma | Sildenafil siltop | Sildenafil tecnigen | Sildenafil teva | Sildenafil toLife | Sildenafil wynn | Sildenafil zentiva | Viagra | Vizarsin;
  • (PY) Paraguay: Almaximo | Dinagram | Dualsex | Levantol | Magnus | Maxdosa | Placer x | Pramil | Pramil forte | Priloc | Procops | Rigix | Rindemax | Ripol | Sacac | Sildenafil citrato | Sildenafil genfar | Sildenafil incomex | Sildenafil medicine | Sildenafil millet | Sildenafil vent 3 | Sobrium | Tenon | Viagra | Vimax | Viril | Zilfic;
  • (QA) Qatar: Aladin | Aphrodil | Caverta | Degra | Silden | Viagra | Zed-100 | Zed-50;
  • (RO) Romania: Balcoga | Granpidam | Mysildecard | Olvion | Revatio | Sildenafil bioeel | Sildenafil medreg | Sildenafil teva | Taxier | Viagra | Vizarsin;
  • (RU) Russian Federation: Caverta | Dynamico | Erexesil | Kamastil | Maxigra | Olmax Strong | Reejump | Revatio | Sealex sildenafil | Silafil | Silden | Sildenafil | Sildenafil cardio | Sildenafil Effax | Sildenafil fpo | Sildenafil zentiva | Taxier | Tornetis | Viagra | Viasan lf | Viatile | Vildegra | Vizarsin | Vizarsin q tab;
  • (SA) Saudi Arabia: Aladin | Aphrodil | Apo sildenafil | Essera | Fallah | Pms sildenafil R | Revatio | Silafil | Turbo | Viagra | Virecta | Virectil | Wafi;
  • (SE) Sweden: Balcoga | Granpidam | Idilico | Mysildecard | Orisild | Revastad | Revatio | Sildenafil | Sildenafil 1a farma | Sildenafil accord | Sildenafil Actavis | Sildenafil aspen | Sildenafil medical valley | Sildenafil orifarm | Sildenafil orion | Sildenafil pfizer | Sildenafil sandoz | Sildenafil stada | Sildenafil teva | Sildorin | Viagra | Vizarsin;
  • (SG) Singapore: A sildenafil | Androz | Ernafil | Remenafil | Sildegra | Sildenafil stada | Viagra | Vivic;
  • (SI) Slovenia: Balcoga | Belfil | Mysildecard | Sildenafil stada | Sildenafil teva | Tornetis | Viagra | Vizarsin;
  • (SK) Slovakia: Amfidor | Balcoga | Ecriten | Eremed | Grasil | Modrasil | Olvion | Revatio | Silandyl | Sildenafil Actavis | Sildenafil Medana | Sildenafil medreg | Sildenafil mylan | Sildenafil Netpharma | Sildenafil ratiopharm | Sildenafil sandoz | Sildenafil saneca | Sildenafil teva | Silfeldrem | Viagra | Vigrande | Viner | Vizarsin;
  • (SL) Sierra Leone: Comit | Power play | Power shooter | Vegon;
  • (TH) Thailand: Elonza | Revatio | Silatio | Sildenafil | Sinafil | Tonafil | Viagra;
  • (TN) Tunisia: Adenafil | Antar | As one | Erecta | Revatio | Sildenafil Actavis | Viadis | Viagra | Viatec | Zoltan;
  • (TR) Turkey: Combo | Degra | Egira | Newagra | Pularter | Retomin | Revatio | Sildegra | Silfect | Silmed | Sinegra | Viagra | Viamed | Vigaroo | Vigrande;
  • (TW) Taiwan: Allnight | Apo sildenafil | Ding hao | Erecter | Fullpower | Ganstrong | Holi up | Jubilant sildenafil | Okpower | Onlee | Penegra | Revatio | Shilifil | Sidneagra | Sife | Silafi | Sildegra | Silden | Sildenafil | Sinaf | Sliting | Slivien | Songra | Uppu | Viagra | Wellnitin | Yto;
  • (UA) Ukraine: Alti met | Conegra | Conegra classic | Erasmo | Erectyl | Ero life | Erosil | Eroton | Filap | Genagra | Intagra ic | Kamafeel | Konegra | Lovigra | Maxigra | Moginin | No-lag | Novagra | Novagra euro | Novigra | Penigra | Penimax | Penimex | Potentiale | Revatio | Silada | Silagra | Sildenafil | Sildenafil ananta | Sildex | Sinegra | Superviga | Tegrum | Vectra | Viagra | Viagra odt | Viasil | Vigramax | Vizarsin | Vizarsin q tab;
  • (UG) Uganda: Astagra | Erecto | Evoke | Giagra 100 | Kamagra | Kamagra 100 | Mardagra | Penegra | Satisfil | Sife | Sildenafil accord | Silmelt | Viagra | Virecta | Vivax | Zeegra | Zoy;
  • (UY) Uruguay: Exitomin | Libiden | Maxfil | Novopramil | Opcion | Plenovit | Segurex | Sildenafil | Sildenafilo | Viagra | Vimax | Vimax odt;
  • (VE) Venezuela, Bolivarian Republic of: Adegra | Dugasek | Durofil light | Duroval | Erbrix | Itaka | Kamagra | Sildenafil | Sildenafil citrato | Sildenafil GC | Sildenafilo | Sildex | Stigmax | Viagra | Viasek | Vigrasol | Vioses | Viridil | Zost;
  • (VN) Viet Nam: Adagrin | Azodra | Daygra | Desilmax | Erecfil | Happygra | Maxxsat | Medovigor | Meyersina | Sibifil | Sifilden | Torfin | Welgra;
  • (ZA) South Africa: Actigra | Avigra | Dynafil | Eraflex | Maklitio | Penimax | Raviag | Revatio | Sildavee | Sildenafil cipla | Sildojub | Silrexia | Silwin | Viagra | Videna | Vigro | Vitrixa;
  • (ZM) Zambia: 7 hours | Aphrodil | Canova | Comit | Cupid | Dr.x | Kamagra | Kifaru | Manforce | Njoi | Perfopil 50 | Seregra | Silagra | Silmet | Ulti-mate | Viagra | Viengray | Virecta | Wingora | Zwagra;
  • (ZW) Zimbabwe: Androz | Avigra | Giagra | Kamagra | Seregra | Viagra
  1. Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015;132(21):2037-2099. doi:10.1161/CIR.0000000000000329 [PubMed 26534956]
  2. Adiga A, Edriss H, Nugent K. Intracranial aneurysm and sildenafil. Proc (Bayl Univ Med Cent). 2016;29(2):178-180. doi:10.1080/08998280.2016.11929407 [PubMed 27034561]
  3. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319. [PubMed 11487763]
  4. Ahsman MJ, Witjes BC, Wildschut ED, et al. Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Arch Dis Child Fetal Neonatal Ed. 2010;95(2):F109-F114. doi:10.1136/adc.2009.168336 [PubMed 19949232]
  5. Al Omar S, Salama H, Al Hail M, et al. Effect of early adjunctive use of oral sildenafil and inhaled nitric oxide on the outcome of pulmonary hypertension in newborn infants. A feasibility study. J Neonatal Perinatal Med. 2016;9(3):251-259. doi:10.3233/NPM-16161 [PubMed 27589542]
  6. Amsterdam EA, Wenger NK, Brindis RG, et al; ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2014;130(25):e433-e434]. Circulation. 2014;130(25):e344-e426. doi:10.1161/CIR.0000000000000134. [PubMed 25249585]
  7. Andersson KE. PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery. Br J Pharmacol. 2018;175(13):2554-2565. doi:10.1111/bph.14205 [PubMed 29667180]
  8. Andrigueti FV, Ebbing PCC, Arismendi MI, Kayser C. Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clin Exp Rheumatol. 2017;35(suppl 106)(4):151-158. [PubMed 28281457]
  9. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 1999;91(1):307-310. doi:10.1097/00000542-199907000-00041 [PubMed 10422958]
  10. Ausó E, Gómez-Vicente V, Esquiva G. Visual side effects linked to sildenafil consumption: An update. Biomedicines. 2021;9(3):291. doi:10.3390/biomedicines9030291 [PubMed 33809319]
  11. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics. 2006;117(4):1077-1083. doi:10.1542/peds.2005-0523 [PubMed 16585301]
  12. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012;125(2):324-334. doi:10.1161/CIRCULATIONAHA.110.016667 [PubMed 22128226]
  13. Barst RJ, Beghetti M, Pulido T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation. 2014;129(19):1914-1923. doi:10.1161/CIRCULATIONAHA.113.005698 [PubMed 24637559]
  14. Bednarz AM, Israel EN, Beckman EJ, Johansen M, Thomas CA. Safety of enteral sildenafil in hemodynamically unstable children. Cardiology in the Young. 2019;29(5):589-593. doi:10.1017/S1047951119000209
  15. Burnett AL, Anele UA, Trueheart IN, Strouse JJ, Casella JF. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med. 2014;127(7):664-668. doi:10.1016/j.amjmed.2014.03.019 [PubMed 24680796]
  16. Campbell UB, Walker AM, Gaffney M, et al. Acute nonarteritic anterior ischemic optic neuropathy and exposure to phosphodiesterase type 5 inhibitors. J Sex Med. 2015;12(1):139-151. doi:10.1111/jsm.12726 [PubMed 25358826]
  17. Cartago RS, Alan PA, Benedicto J. Pregnancy outcomes in patients with severe pulmonary hypertension and Eisenmenger syndrome treated with sildenafil monotherapy. Obstet Med. 2014;7(1):40-42. doi:10.1177/1753495X13514403 [PubMed 27512419]
  18. Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm [PubMed 6810084]
  19. Chen J, Mabjeesh NJ, Greenstein A, Nadu A, Matzkin H. Clinical efficacy of sildenafil in patients on chronic dialysis. J Urol. 2001;165(3):819-821. [PubMed 11176477]
  20. Chetan C, Suryawanshi P, Patnaik S, et al. Oral versus intravenous sildenafil for pulmonary hypertension in neonates: a randomized trial. BMC Pediatr. 2022;22(1):311. doi:10.1186/s12887-022-03366-3 [PubMed 35624452]
  21. Cochius-den Otter SCM, Kipfmueller F, de Winter BCM, et al. Pharmacokinetic modeling of intravenous sildenafil in newborns with congenital diaphragmatic hernia. Eur J Clin Pharmacol. 2020;76(2):219-227. doi:10.1007/s00228-019-02767-1 [PubMed 31740991]
  22. Cohen JL, Nees SN, Valencia GA, Rosenzweig EB, Krishnan US. Sildenafil use in children with pulmonary hypertension. J Pediatr. 2019;205:29-34.e1. doi:10.1016/j.jpeds.2018.09.067 [PubMed 30396684]
  23. Darland LK, Dinh KL, Kim S, et al. Evaluating the safety of intermittent intravenous sildenafil in infants with pulmonary hypertension. Pediatr Pulmonol. 2017;52(2):232-237. doi:10.1002/ppul.23503 [PubMed 27340796]
  24. Dunn L, Greer R, Flenady V, Kumar S. Sildenafil in pregnancy: a systematic review of maternal tolerance and obstetric and perinatal outcomes. Fetal Diagn Ther. 2017;41(2):81-88. doi:10.1159/000453062 [PubMed 27926905]
  25. Dunn L, Flenady V, Kumar S. Reducing the risk of fetal distress with sildenafil study (RIDSTRESS): a double-blind randomised control trial. J Transl Med. 2016;14:15. doi:10.1186/s12967-016-0769-0 [PubMed 26767411]
  26. El-Ghandour M, Hammad B, Ghanem M, Antonios MAM. Efficacy of milrinone plus sildenafil in the treatment of neonates with persistent pulmonary hypertension in resource-limited settings: results of a randomized, double-blind trial. Paediatr Drugs. 2020;22(6):685-693. doi:10.1007/s40272-020-00412-4 [PubMed 32856285]
  27. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  28. Fender RA, Hasselman TE, Wang Y, Harthan AA. Evaluation of the tolerability of intermittent intravenous sildenafil in pediatric patients with pulmonary hypertension. J Pediatr Pharmacol Ther. 2016;21(5):419-425. doi:10.5863/1551-6776-21.5.419 [PubMed 27877095]
  29. Fraisse A, Butrous G, Taylor MB, Oakes M, Dilleen M, Wessel DL. Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med. 2011;37(3):502-509. doi:10.1007/s00134-010-2065-4 [PubMed 21069290]
  30. Fries R, Shariat K, von Wilmowsky H, Böhm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005;112(19):2980-2985. doi:10.1161/CIRCULATIONAHA.104.523324 [PubMed 16275885]
  31. Galiè N, Ghofrani HA, Torbicki A, et al; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension [published correction appears in N Engl J Med. 2006;354(22):2400-2401]. N Engl J Med. 2005;353(20):2148-2157. [PubMed 16291984]
  32. Galiè N, Müller K, Scalise AV, Grünig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015;45(5):1314-1322. doi:10.1183/09031936.00105914 [PubMed 25657022]
  33. Gallagher SA, Hackett P. High altitude pulmonary edema. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed October 10, 2022.
  34. Ghafari A, Farshid B, Afshari AT, et al. Sildenafil citrate can improve erectile dysfunction among chronic hemodialysis patients. Indian J Nephrol. 2010;20(3):142-145. doi:10.4103/0971-4065.70845 [PubMed 21072154]
  35. Ghiadoni L, Versari D, Taddei S. Phosphodiesterase 5 inhibition in essential hypertension. Curr Hypertens Rep. 2008;10(1):52-57. doi:10.1007/s11906-008-0011-4 [PubMed 18367027]
  36. Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract. 2010;64(2):240-255. doi:10.1111/j.1742-1241.2009.02254.x [PubMed 19900167]
  37. Groom KM, Ganzevoort W, Alfirevic Z, Lim K, Papageorghiou AT; STRIDER Consortium. Clinicians should stop prescribing sildenafil for fetal growth restriction (FGR): comment from the STRIDER Consortium. Ultrasound Obstet Gynecol. 2018;52(3):295-296. doi:10.1002/uog.19186 [PubMed 30079989]
  38. Groom KM, McCowan LM, Mackay LK, et al. STRIDER NZAus: a multicentre randomised controlled trial of sildenafil therapy in early-onset fetal growth restriction. BJOG. 2019;126(8):997-1006. doi:10.1111/1471-0528.15658 [PubMed 30779295]
  39. Grossman EB, Swan SK, Muirhead GJ, et al. The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients. Kidney Int. 2004;66(1):367-374. doi:10.1111/j.1523-1755.2004.00739.x [PubMed 15200445]
  40. Hayat S, Al-Mutairy M, Zubaid M, Suresh C. Acute myocardial infarction following sildenafil intake in a nitrate-free patient without previous history of coronary artery disease. Med Princ Pract. 2007;16(3):234-236. doi:10.1159/000100397 [PubMed 17409761]
  41. Hsu CH, Gomberg-Maitland M, Glassner C, et al. The management of pregnancy and pregnancy-related medical conditions in pulmonary arterial hypertension patients. Int J Clin Pract Suppl. 2011;172:6-14. [PubMed 21736676]
  42. Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237 [PubMed 36017548]
  43. Humpl T, Reyes JT, Erickson S, et al. Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease. Cardiol Young. 2011;21(2):187-193. [PubMed 21138617]
  44. Hussain AS, Ali R, Ahmed S, Naz F, Haroon A. Oral sildenafil use in neonates with persistent pulmonary hypertension of newborn. J Ayub Med Coll Abbottabad. 2017;29(4):677-680. [PubMed 29331003]
  45. Hussain WA, Bondi DS, Shah P, Morgan SE, Sriram S, Schreiber MD. Implementation of an inhaled nitric oxide weaning protocol and stewardship in a level 4 NICU to decrease inappropriate use. J Pediatr Pharmacol Ther. 2022;27(3):284-291. doi:10.5863/1551-6776-27.3.284 [PubMed 35350163]
  46. "Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  47. Juergense PH, Botev R, Wuerth D, Finkelstein SH, Smith JD, Finkelstein FO. Erectile dysfunction in chronic peritoneal dialysis patients: incidence and treatment with sildenafil. Perit Dial Int. 2001;21(4):355-359. [PubMed 11587397]
  48. Kamran A, Rafiq N, Khalid A, et al. Effectiveness of oral sildenafil for neonates with persistent pulmonary hypertension of newborn (PPHN): a prospective study in a tertiary care hospital. J Matern Fetal Neonatal Med. 2022;35(25):6787-6793. doi:10.1080/14767058.2021.1923003 [PubMed 33980104]
  49. Khan AS, Sheikh Z, Khan S, Dwivedi R, Benjamin E. Viagra deafness--sensorineural hearing loss and phosphodiesterase-5 inhibitors. Laryngoscope. 2011;121(5):1049-1054. doi:10.1002/lary.21450 [PubMed 21520123]
  50. Karaarslan C. Ocular side effects of sildenafil that persist beyond 24 h-A case series. Front Neurol. 2020;11:67. doi:10.3389/fneur.2020.00067 [PubMed 32117027]
  51. Khera M, Cunningham GR. Treatment of male sexual dysfunction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 11, 2020.
  52. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. Chest. 2019;155(3):565-586. doi:10.1016/j.chest.2018.11.030 [PubMed 30660783]
  53. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation. 2004;110(19):3149-3155. doi:10.1161/01.CIR.0000146906.42375.D3 [PubMed 15533876]
  54. Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol. 2005;96(12B):42M-46M. doi:10.1016/j.amjcard.2005.07.011 [PubMed 16387566]
  55. Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909 [PubMed 27941129]
  56. Krishnan U, Feinstein JA, Adatia I, et al. Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia. J Pediatr. 2017;188:24-34.e1. doi:10.1016/j.jpeds.2017.05.029 [PubMed 28645441]
  57. Lee JE, Hillier SC, Knoderer CA. Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease. J Intensive Care Med. 2008;23(5):329-334. doi:10.1177/0885066608321389 [PubMed 18701525]
  58. Lee Y, Park KA, Oh SY, Min JH, Kim BJ. Fourth cranial nerve palsy associated with sildenafil citrate. J Neuroophthalmol. 2021;41(1):e79-e80. doi:10.1097/WNO.0000000000000938 [PubMed 32235216]
  59. Levin G, Rottenstreich A. Sildenafil citrate in obstetrics - caution is advised. BJOG. 2019;126(6):736. doi:10.1111/1471-0528.15605 [PubMed 30773787]
  60. Li WQ, Qureshi AA, Robinson KC, Han J. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med. 2014;174(6):964-970. [PubMed 24710960]
  61. Lim K, Chang SA, Oh SY, et al. Pulmonary arterial hypertension and pregnancy: single center experience in current era of targeted therapy. Korean Circ J. 2019;49(6):545-554. doi:10.4070/kcj.2018.0350 [PubMed 31074218]
  62. Liqrev (sildenafil) [prescribing information]. Farmville, NC: CMP Pharma Inc; April 2023.
  63. Liu B, Zhu L, Zhong J, Zeng G, Deng T. The association between phosphodiesterase type 5 inhibitor use and risk of non-arteritic anterior ischemic optic neuropathy: A systematic review and meta-analysis. Sex Med. 2018;6(3):185-192. doi:10.1016/j.esxm.2018.03.001 [PubMed 29884471]
  64. Loeb S, Folkvaljon Y, Lambe M, et al. Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA. 2015;313(24):2449-2455. [PubMed 26103029]
  65. Lowe G, Costabile RA. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. J Sex Med. 2012;9(1):265-270. doi:10.1111/j.1743-6109.2011.02537.x [PubMed 22023666]
  66. Luks AM, Auerbach PS, Freer L, et al. Wilderness Medical Society clinical practice guidelines for the prevention and treatment of acute altitude illness: 2019 update. Wilderness Environ Med. 2019;30(4S):S3-S18. doi:10.1016/j.wem.2019.04.006 [PubMed 31248818]
  67. Machado RF, Barst RJ, Yovetich NA, et al; walk-PHaSST Investigators and Patients. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood. 2011;118(4):855-864. doi:10.1182/blood-2010-09-306167 [PubMed 21527519]
  68. Maddox PT, Saunders J, Chandrasekhar SS. Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology. Laryngoscope. 2009;119(8):1586-1589. doi:10.1002/lary.20511 [PubMed 19507217]
  69. Maged M, Wageh A, Shams M, Elmetwally A. Use of sildenafil citrate in cases of intrauterine growth restriction (IUGR); a prospective trial. Taiwan J Obstet Gynecol. 2018;57(4):483-486. doi:10.1016/j.tjog.2018.06.002 [PubMed 30122565]
  70. Maher MA, Sayyed TM, El-Khadry SW. Nifedipine alone or combined with sildenafil citrate for management of threatened preterm labour: a randomised trial. BJOG. 2019;126(6):729-735. doi:10.1111/1471-0528.15503 [PubMed 30315625]
  71. Mahmoud A, Abid F, Khairallah M, et al. Case report: central retinal artery occlusion following sildenafil intake. F1000Res. 2022;11:600. doi:10.12688/f1000research.122087.1 [PubMed 36249994]
  72. Mahon A, Sidhu PS, Muir G, Macdougall IC. The efficacy of sildenafil for the treatment of erectile dysfunction in male peritoneal dialysis patients. Am J Kidney Dis. 2005;45(2):381-387. doi:10.1053/j.ajkd.2004.10.012 [PubMed 15685517]
  73. McGwin G Jr. Phosphodiesterase type 5 inhibitor use and hearing impairment. Arch Otolaryngol Head Neck Surg. 2010;136(5):488-492. doi:10.1001/archoto.2010.51 [PubMed 20479381]
  74. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573-1619. [PubMed 19389575]
  75. Morgan JC, Alhatou M, Oberlies J, Johnston KC. Transient ischemic attack and stroke associated with sildenafil (Viagra) use. Neurology. 2001;57(9):1730-1731. doi:10.1212/wnl.57.9.1730 [PubMed 11706126]
  76. Moschos MM, Nitoda E. Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction. Drug Des Devel Ther. 2016;8:3407-3413. doi:10.2147/DDDT.S118015 [PubMed 27799745]
  77. Mourani PM, Sontag MK, Ivy DD, et al. Effects of Long-Term Sildenafil Treatment for Pulmonary Hypertension in Infants With Chronic Lung Disease. J Pediatr. 2009;154(3):379-84. [PubMed 18950791]
  78. Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br J Clin Pharmacol. 2002;53(suppl 1):21S-30S. doi:10.1046/j.0306-5251.2001.00029.x [PubMed 11879256]
  79. Mukherjee A, Dombi T, Wittke B, et al. Population pharmacokinetics of sildenafil in term neonates: Evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther. 2009;85(1):56-63. [PubMed 18800037]
  80. Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med. 2006;174(9):1042-1047. doi:10.1164/rccm.200605-694OC [PubMed 16917115]
  81. Nathoo NA, Etminan M, Mikelberg FS. Association between phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 2015;35(1):12-15. doi:10.1097/WNO.0000000000000186 [PubMed 25295683]
  82. Nemoto S, Sasaki T, Ozawa H, et al. Oral sildenafil for persistent pulmonary hypertension early after congenital cardiac surgery in children. Eur J Cardiothorac Surg. 2010;38(1):71-77. doi:10.1016/j.ejcts.2010.01.045 [PubMed 20206543]
  83. Novick WM, Golovenko OS, Lazorhyshynets VV, Dedovich VV, DiSessa TG. Sildenafil's early, late impact on ventricular septal repair: older children using the double patch. Ann Thorac Surg. 2022;114(3):818-825. doi:10.1016/j.athoracsur.2021.06.018 [PubMed 34228973]
  84. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2013;128(25):e481.] Circulation. 2013;127(4):e362-e425. [PubMed 23247304]
  85. Okuyucu S, Guven OE, Akoglu E, Uçar E, Dagli S. Effect of phosphodiesterase-5 inhibitor on hearing. J Laryngol Otol. 2009;123(7):718-722. doi:10.1017/S002221510900423X [PubMed 19134242]
  86. Palma G, Giordano R, Russolillo V, et al. Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery. Tex Heart Inst J. 2011;38(3):238-242. [PubMed 21720460]
  87. Pawar T, Saboo K, Patel M, Kumar S, Acharya S. Sildenafil-induced acute fulminant hepatic failure: tragedy after triumph. Cureus. 2022;14(7):e27378. doi:10.7759/cureus.27378 [PubMed 36046329]
  88. Pels A, Kenny LC, Alfirevic Z, et al; international STRIDER Consortium. STRIDER (Sildenafil Therapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials. BMC Pregnancy Childbirth. 2017;17(1):440. doi:10.1186/s12884-017-1594-z [PubMed 29282009]
  89. Pierce CM, Zhang MH, Jonsson B, et al. Efficacy and safety of IV sildenafil in the treatment of newborn infants with, or at risk of, persistent pulmonary hypertension of the newborn (PPHN): a multicenter, randomized, placebo-controlled trial. J Pediatr. 2021;237:154-161.e3. doi:10.1016/j.jpeds.2021.05.051 [PubMed 34052232]
  90. Qasim A, Dasgupta S, Aly AM, Jain SK. Sildenafil use in the treatment of bronchopulmonary dysplasia-associated pulmonary hypertension: a case series. AJP Rep. 2018;8(4):e219-e222. doi:10.1055/s-0038-1673343 [PubMed 30345157]
  91. Refer to manufacturer's labeling.
  92. Regenold J, Ghoraba H, Akhavanrezayat A, et al. Unilateral acute anterior uveitis with macular edema following the use of sildenafil citrate in a patient with HLA-B27 positivity. Am J Ophthalmol Case Rep. 2021;24:101228. doi:10.1016/j.ajoc.2021.101228 [PubMed 34761138]
  93. Revatio (sildenafil citrate) [prescribing information]. Morgantown, WV: Viatris Specialty LLC; January 2023.
  94. Revatio (sildenafil citrate) [product monograph]. Kirkland, Quebec, Canada: Upjohn Canada ULC; February 2021.
  95. Rezaee ME, Gross MS. Are we overstating the risk of priapism with oral phosphodiesterase type 5 inhibitors? J Sex Med. 2020;17(8):1579-1582. doi:10.1016/j.jsxm.2020.05.019 [PubMed 32622767]
  96. Rhee SJ, Shin SH, Oh J, et al. Population pharmacokinetic analysis of sildenafil in term and preterm infants with pulmonary arterial hypertension. Sci Rep. 2022;12(1):7393. doi:10.1038/s41598-022-11038-6 [PubMed 35513541]
  97. Rosas SE, Wasserstein A, Kobrin S, Feldman HI. Preliminary observations of sildenafil treatment for erectile dysfunction in dialysis patients. Am J Kidney Dis. 2001;37(1):134-137. doi:10.1053/ajkd.2001.20608 [PubMed 11136178]
  98. Roustit M, Blaise S, Allanore Y, Carpentier PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomized trials. Ann Rheum Dis. 2013;72(10):1696-1699. doi:10.1136/annrheumdis-2012-202836 [PubMed 23426043]
  99. Roustit M, Giai J, Gaget O, et al. On-demand sildenafil as a treatment for Raynaud phenomenon: a series of n-of-1 trials. Ann Intern Med. 2018;169(10):694-703. doi:10.7326/M18-0517 [PubMed 30383134]
  100. Rubin LJ, Badesch DB, Fleming TR, et al; SUPER-2 Study Group. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011;140(5):1274-1283. doi:10.1378/chest.10-0969 [PubMed 21546436]
  101. Russo FM, Conings S, Allegaert K, et al. Sildenafil crosses the placenta at therapeutic levels in a dually perfused human cotyledon model. Am J Obstet Gynecol. 2018;219(6):619.e1-619.e10. doi:10.1016/j.ajog.2018.08.041 [PubMed 30194048]
  102. Sauer WH, Kimmel SE. Sexual activity in patients with cardiovascular disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 23, 2020.
  103. Seibel I, Poli De Figueiredo CE, Telöken C, Moraes JF. Efficacy of oral sildenafil in hemodialysis patients with erectile dysfunction. J Am Soc Nephrol. 2002;13(11):2770-2775. doi:10.1097/01.asn.0000034201.97937.3e [PubMed 12397048]
  104. Shalbafan M, Orooji M, Kamalzadeh L. Psychosis beas a rare side effect of sildenafil: a case report. J Med Case Rep. 2022;16(1):120. doi:10.1186/s13256-022-03334-6 [PubMed 35337380]
  105. Sharma VK, Joshi S, Joshi A, Kumar G, Arora H, Garg A. Does intravenous sildenafil clinically ameliorate pulmonary hypertension during perioperative management of congenital heart diseases in children? - a prospective randomized study. Ann Card Anaesth. 2015;18(4):510-516. doi:10.4103/0971-9784.166457 [PubMed 26440237]
  106. Sharma C, Burns J, Kulkarni A, Cerise JE, Molina Berganza F, Hayes DA. Continuous and intermittent administration of intravenous sildenafil in critically ill infants with pulmonary hypertension. Pediatr Pulmonol. 2021;56(9):2973-2978. doi:10.1002/ppul.25539 [PubMed 34143564]
  107. Sharp A, Cornforth C, Jackson R, et al; STRIDER group. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial [published correction appears in Lancet Child Adolesc Health. 2018;2(2):e2]. Lancet Child Adolesc Health. 2018;2(2):93-102. doi:10.1016/S2352-4642(17)30173-6 [PubMed 30169244]
  108. Steinhorn RH, Kinsella JP, Pierce C, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr. 2009;155(6):841-847. [PubMed 19836028]
  109. Stultz JS, Puthoff T, Backes C Jr, Nahata MC. Intermittent intravenous sildenafil for pulmonary hypertension management in neonates and infants. Am J Health Syst Pharm. 2013;70(5):407-413. doi:10.2146/ajhp120364 [PubMed 23413163]
  110. Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest. 2014;146(2):449-475. doi:10.1378/chest.14-0793 [PubMed 24937180]
  111. Tan K, Krishnamurthy MB, O'Heney JL, Paul E, Sehgal A. Sildenafil therapy in bronchopulmonary dysplasia-associated pulmonary hypertension: a retrospective study of efficacy and safety. Eur J Pediatr. 2015;174(8):1109-1115. doi:10.1007/s00431-015-2515-7 [PubMed 25796626]
  112. Trottier-Boucher MN, Lapointe A, Malo J, et al. Sildenafil for the treatment of pulmonary arterial hypertension in infants with bronchopulmonary dysplasia. Pediatr Cardiol. 2015;36(6):1255-1260. doi:10.1007/s00246-015-1154-0 [PubMed 25824807]
  113. Türk S, Karalezli G, Tonbul HZ, et al. Erectile dysfunction and the effects of sildenafil treatment in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2001;16(9):1818-1822. doi:10.1093/ndt/16.9.1818 [PubMed 11522864]
  114. Uhm JY, Jhang WK, Park JJ, et al. Postoperative use of oral sildenafil in pediatric patients with congenital heart disease. Pediatr Cardiol. 2010;31(4):515-520. [PubMed 20054528]
  115. Vachiery JL, Huez S, Gillies H, et al. Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. Br J Clin Pharmacol. 2011;71(2):289-292. doi:10.1111/j.1365-2125.2010.03831.x [PubMed 21219411]
  116. Vargas-Origel A, Gómez-Rodríguez G, Aldana-Valenzuela C, Vela-Huerta MM, Alarcón-Santos SB, Amador-Licona N. The use of sildenafil in persistent pulmonary hypertension of the newborn. Am J Perinatol. 2010;27(3):225-230. doi:10.1055/s-0029-1239496 [PubMed 19866403]
  117. Vassalos A, Peng E, Young D, et al. Pre-operative sildenafil and pulmonary endothelial-related complications following cardiopulmonary bypass: A randomised trial in children undergoing cardiac surgery. Anaesthesia. 2011;66(6):472-480. [PubMed 21457152]
  118. Viagra (sildenafil citrate) [prescribing information]. New York, NY: Pfizer Labs; December 2017.
  119. Viagra (sildenafil citrate) [product monograph]. Kirkland, Quebec, Canada: Upjohn Canada Inc; May 2020.
  120. Wigley FM. Treatment of Raynaud phenomenon: Initial management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed January 31, 2020.
  121. Wollein U, Schech B, Hardt J, Schramek N. Determination and quantitation of sildenafil and its major metabolite in the breast milk of a lactating woman. J Pharm Biomed Anal. 2016;120:100-105. doi:10.1016/j.jpba.2015.12.006 [PubMed 26717019]
  122. Yafi FA, Sharlip ID, Becher EF. Update on the safety of phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. Sex Med Rev. 2018;6(2):242-252. doi:10.1016/j.sxmr.2017.08.001 [PubMed 28923561]
  123. YeniçerioGlu Y, Kefi A, Aslan G, et al. Efficacy and safety of sildenafil for treating erectile dysfunction in patients on dialysis. BJU Int. 2002;90(4):442-445. doi:10.1046/j.1464-410x.2002.02914.x [PubMed 12175405]
  124. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999;83(5A):35C-44C. doi:10.1016/s0002-9149(99)00046-6 [PubMed 10078541]
Topic 13000 Version 650.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟